This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content
VANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC), today announced that Robert E. Hoffman, Chief Financial Officer, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17th, 2026.
Sign In or Create an Account
or View more offersArticle content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
DATE: Thursday, September 17, 2026
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article contentArticle content
TIME: 12:30 PM PT / 3:30 PM ET
Article content
Article content
The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.
Article content
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Article content
Learn more about the event at www.virtualinvestorconferences.com.
Article content
About CytoDyn
Article content
CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
For more information, please visit www.cytodyn.com and follow us on LinkedIn.
Article content
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Article content
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Article content
CONTACTS:
Article content
CytoDyn Corporate
Article content
CytoDyn Media
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
[email protected]
Article content
Virtual Investor Conferences
Greg Young
VP Corporate Services, Investor Access
OTC Markets Group
(212) 652-5958
[email protected]
Article contentArticle content
Article contentArticle contentArticle contentArticle content